We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Improved Treatment for Malignant Hyperthermia During Surgery

By HospiMedica staff writers
Posted on 21 May 2008
Instantaneous reconstituted Dantrolene Sodium for injection represents an advancement in the pharmacotherapy of patients experiencing malignant hyperthermia (MH) during surgery.

Dantrolene Sodium for Injection is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle, characteristic of MH crises in patients of all ages. More...
It is also indicated preoperatively and sometimes postoperatively in individuals judged to be MH susceptible. Currently, intravenous (IV) dantrolene sodium is the only product indicated to treat MH; however, with up to 36 vials of dantrolene sodium needed to treat one case of this condition, the enhanced speed of reconstitution--20 seconds or less--represents a distinct advantage to a physician faced with the task of administering enough product to reverse this time-sensitive reaction before permanent damage or death can occur.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have also been rare reports of urticaria and erythema possibly associated with the administration of IV dantrolene sodium. The Dantrolene Sodium for Injection, a product of US WorldMeds (Louisville, KY, USA), and the company plans to file a submission for U.S. Food and Drug Administration (FDA) approval during 2008. Dantrolene Sodium for Injection with improved reconstitution is the only generic substitute for Dantrium Intravenous (IV), a registered trade name of Procter & Gamble (Cincinnati, OH, USA).

"This enhanced reconstitution time is an important improvement to intravenous dantrolene sodium, the first advance for this life saving treatment in 30 years,” said anesthesiologist Dr. Richard Morris.

Malignant hyperthermia is a rare life-threatening condition that is triggered by exposure to certain drugs used for general anesthesia (specifically all volatile anesthetics), nearly all gas anesthetics, and the neuromuscular blocking agent succinylcholine. In susceptible individuals, these drugs can induce a drastic and uncontrolled increase in skeletal muscle oxidative metabolism, which overwhelms the body's capacity to supply oxygen, remove carbon dioxide, and regulate body temperature, eventually leading to circulatory collapse and death if untreated.


Related Links:
US WorldMeds
Procter & Gamble

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.